[Dantrium in the treatment of increased muscle tonus in patients with multiple sclerosis].
In 19 patients with multiple sclerosis and 1 with subacute sclerosing panencephalitis the mean increase in muscle tonus was found to be 3.1 (range 1--4 according to Burke-Ashwort). In 10 controls with multiple sclerosis the mean spasticity was 2.4. Dantrium was given in doses up to 800 mg for 14--16 days and it caused a greater reduction of spasticity than placebo (p less than 0.05). In 12 patients (60%) varying degrees of muscle tonus reduction was observed. In 11 patients the efect of Dantrium was compared with that of other drugs (Clonazepam, Tetradiazepam, Carisoprodol and Lyoresal). In 6 cases Dantrium was a more effective drug than other muscle relaxants and in 5 cases no difference was observed or other drugs were superior to Dantrium.
D000328:Adult; D002328:Carisoprodol / Q000494:pharmacology; D002986:Clinical Trials as Topic; D002998:Clonazepam / Q000494:pharmacology; D003620:Dantrolene / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D003975:Diazepam / Q000494:pharmacology; D004576:Electromyography; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009129:Muscle Tonus / Q000187:drug effects*
D006827:Hydantoins; D002328:Carisoprodol; D002998:Clonazepam; D003620:Dantrolene; D003975:Diazepam
Dantrium w leczeniu wzmozonego napiecia mieśniowego u chorych na stwardnienie rozsiane